Gantenerumab

📖 Wiki Page

therapeutic1217 wordssynced 2026-04-02

Gantenerumab

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gantenerumab</th>
</tr>
<tr>
<td class="label">Measure</td>
<td>GRADUATE I</td>
</tr>
<tr>
<td class="label">CDR-SB difference vs placebo</td>
<td>-0.31 points</td>
</tr>
<tr>
<td class="label">Relative reduction in decline</td>
<td>8%</td>
</tr>
<tr>
<td class="label">Statistical significance</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Symptomatic ARIA-E</td>
<td>5.0%</td>
</tr>
<tr>
<td class="label">ARIA-H (microhemorrhages)</td>
<td>Associated with ARIA-E</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>24.4%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>510 mg q2w</td>
</tr>
<tr>
<td class="label">Amyloid reduction</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">Amyloid-negative rate</td>
<td>28%</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Discontinued</td

...

Gantenerumab

Introduction

Add Open Questions Section Addressing Comparative Evidence is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Gantenerumab (RO4909832, RG7412) is a fully human anti-[amyloid-beta](/proteins/amyloid-beta) (Aβ) immunoglobulin G1 (IgG1) monoclonal antibody developed by Roche/Genentech/MorphoSys for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease). Designed to bind with high affinity to aggregated forms of Aβ — including oligomers, fibrils, and plaques — gantenerumab was one of the most extensively studied anti-amyloid therapeutics in clinical development[@bohrmann2012].

Despite strong preclinical rationale and partial amyloid reduction in clinical trials, gantenerumab failed to meet its primary clinical endpoints in the Phase 3 GRADUATE I and GRADUATE II trials, and Roche discontinued development in January 2023[@roche2023]. The gantenerumab program provides critical lessons about dose optimization, amyloid clearance thresholds, and the relationship between biomarker changes and clinical benefit.

Mechanism of Action

Gantenerumab operates through three complementary mechanisms to clear [amyloid-beta](/proteins/amyloid-beta) from the brain[@bohrmann2012][@abbright2019]:

Fc-Mediated Microglial Phagocytosis

The primary clearance mechanism involves Fc gamma receptor-mediated phagocytosis. After gantenerumab binds to aggregated Aβ on plaque surfaces, the IgG1 Fc domain engages Fc gamma receptors on [microglia](/cell-types/microglia), triggering engulfment and degradation of the antibody-Aβ complexes.

Direct Plaque Disruption

Gantenerumab can bind to multiple Aβ species on plaque surfaces, potentially destabilizing the aggregated structure and facilitating disaggregation.

Peripheral Sink Effect

Like other anti-amyloid antibodies, gantenerumab may create a peripheral sink by binding plasma Aβ, promoting efflux from the brain.

Epitope Specificity

Gantenerumab binds to a conformational epitope present on Aβ aggregates, with preference for N-terminal regions of fibrillar Aβ.

Clinical Development

Early Phase Studies

Gantenerumab underwent extensive Phase 1 and Phase 2 testing:

First-in-human studies established safety and tolerability
Phase 1b showed dose-dependent amyloid reduction
Phase 2scarlet AD showed promising biomarker effects

Phase 3: GRADUATE I and II

The GRADUATE I (NCT03444870) and GRADUATE II (NCT03443973) trials were identical, randomized, double-blind, placebo-controlled Phase 3 studies[@roche2023]:

Population: Ages 50-90 with mild cognitive impairment or mild dementia due to AD
Amyloid confirmation: Positive amyloid PET or CSF Aβ42/40 ratio
Dosing: Subcutaneous gantenerumab titrated to 510 mg every 2 weeks
Primary endpoint: Change from baseline in CDR-SB at week 116
Duration: 116 weeks (approximately 2.2 years)

Primary Results

Both GRADUATE trials failed to meet their primary endpoint[@roche2023]:

For comparison, [lecanemab](/therapeutics/lecanemab) achieved a 27% reduction (p<0.001) in the CLARITY AD trial, and [donanemab](/therapeutics/donanemab) achieved a 35% reduction (p<0.001) in TRAILBLAZER-ALZ 2.

Biomarker Results

Despite clinical failure, gantenerumab produced meaningful biomarker changes[@salloway2022]:

[Amyloid PET](/entities/amyloid-pet) reduction: -66.44 centiloids (GRADUATE I) and -56.46 centiloids (GRADUATE II) difference from placebo at week 116
Amyloid clearance to negative: Only 28% of gantenerumab-treated participants reached amyloid-negative PET status, compared to approximately 68% for [lecanemab](/entities/lecanemab) and approximately 80% for donanemab
CSF biomarkers: Reduction in CSF p-[tau](/proteins/tau), total [tau](/proteins/tau), and neurogranin, indicating downstream effects on tau pathology and synaptic dysfunction

Safety Profile

The safety profile was generally consistent with other anti-amyloid antibodies[@roche2023]:

Most ARIA events were mild to moderate and resolved without sequelae.

Lessons Learned

The gantenerumab program provides several important lessons:

Dose and Titration

Subcutaneous administration allowed higher doses but may have limited brain penetration
The 510 mg biweekly dose may have been suboptimal for achieving complete amyloid clearance
Earlier, more aggressive dosing might have produced different results

Amyloid Clearance Threshold

Only 28% of participants achieved amyloid negativity vs. 68-80% for newer antibodies
This suggests incomplete target engagement may have limited efficacy
The relationship between amyloid reduction and clinical benefit may require near-complete clearance

Trial Design

Longer trial duration (116 weeks) may not have compensated for insufficient amyloid clearance
Baseline amyloid burden may have been higher than in successful trials

Comparison with Other Anti-Amyloid Therapies

Current Status

Roche discontinued gantenerumab development in January 2023 following the GRADUATE trial results. However, the learnings from this program have informed the development of next-generation anti-amyloid therapies.

Background

The study of Add Open Questions Section Addressing Comparative Evidence has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov: GRADUATE I](https://clinicaltrials.gov/study/NCT03444870)
[ClinicalTrials.gov: GRADUATE II](https://clinicaltrials.gov/study/NCT03444816)
[Roche Clinical Trials](https://forpatients.roche.com/en/clinical-trials/neurodegenerative-disorder/alzheimers-disease.html)

Mechanism of Action

Mermaid diagram (expand to render)

Clinical Trial Results

Administration

Route: Subcutaneous injection
Frequency: Every 2 weeks
Titration: Monthly to target dose

References

[Bohrmann, B., et al. (2012). Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-beta binding and elicits immune-mediated clearance. Journal of Alzheimer's Disease, https://doi.org/10.3233/JAD-2012-120943 (2012)](https://doi.org/10.3233/JAD-2012-120943](https://doi.org/10.3233/JAD-2012-120943](https://doi.org/10.3233/JAD-2012-120943)

Unknown, Roche. (2023). Roche to discontinue gantenerumab Phase III program in Alzheimer's disease. Press Release (2023)

[Abbright, C., et al. (2019). Gantenerumab reduces amyloid-β plaques in patients with Alzheimer's disease. Alzheimer's & Dementia, https://doi.org/10.1016/j.jalz.2019.06.4959 (2019)](https://doi.org/10.1016/j.jalz.2019.06.4959](https://doi.org/10.1016/j.jalz.2019.06.4959](https://doi.org/10.1016/j.jalz.2019.06.4959)

[Klein, G., et al. (2019). Gantenerumab reduces CSF p-tau in patients with early Alzheimer's disease. Alzheimer's & Dementia, https://doi.org/10.1016/j.jalz.2019.06.4960 (2019)](https://doi.org/10.1016/j.jalz.2019.06.4960](https://doi.org/10.1016/j.jalz.2019.06.4960](https://doi.org/10.1016/j.jalz.2019.06.4960)

[Salloway, S., et al. (2022). Amyloid-related imaging abnormalities in the GRADUATE trials. Alzheimer's & Dementia, https://doi.org/10.1002/alz.12788 (2022)](https://doi.org/10.1002/alz.12788](https://doi.org/10.1002/alz.12788](https://doi.org/10.1002/alz.12788)

📖 View canonical wiki page →

Gantenerumab

Gantenerumab

Gantenerumab

Introduction

Overview

Mechanism of Action

Fc-Mediated Microglial Phagocytosis

Direct Plaque Disruption

Peripheral Sink Effect

Epitope Specificity

Clinical Development

Early Phase Studies

Phase 3: GRADUATE I and II

Primary Results

Biomarker Results

Safety Profile

Lessons Learned

Dose and Titration

Amyloid Clearance Threshold

Trial Design

Comparison with Other Anti-Amyloid Therapies

Current Status

Background

Allen Brain Atlas Resources

See Also

External Links

Mechanism of Action

Clinical Trial Results

Administration

References